middle.news
EMVision Advances FDA Trial and Pre-Hospital Studies with $18.4m Cash Reserve
9:12am on Monday 13th of April, 2026 AEST
•
Healthcare
Read Story
EMVision Advances FDA Trial and Pre-Hospital Studies with $18.4m Cash Reserve
9:12am on Monday 13th of April, 2026 AEST
Key Points
Eight hospitals actively recruiting in FDA pivotal trial with no device-related adverse events
Pre-hospital feasibility studies for First Responder device nearing completion
Received $3.8 million R&D tax refund for FY25 and $0.4 million milestone grant payment
Cash reserves stand at $18.4 million with $6.6 million in remaining non-dilutive grant funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE